MLXIPL and fatty liver disease: Thus, while knockdown of ChREBP reduces Dex-induced glycolysis, it does not attenuate chronic Dex-induced hypertriglyceridemia and hepatic steatosis despite the decreased expression of certain lipogenic genes.